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The current standard therapeutic regimen for the 
people with locally-advanced non-small cell lung 
cancer (NSCLC) without a mutation is platinum-
based double-agent chemotherapy. Their effective-
ness against NSCL and systemic toxicity must be 
known in advance to utilize these drugs effectively.  
Many biomarkers have emerged as prognostic 
and predictive markers for NSCLC. Among them, the 
common biomarkers are the epidermal growth factor 
receptor (EGFR), 5 endonuclease enzyme of nu-
cleotide excision repair (ERCC1), Kirsten sarcoma 
virus, which is a proto-oncogene (K-ras), and regula-
tor subunit of ribonucleotide reductase. Besides, there 
is huge evidence suggesting that there might be a 
prognosis between NSCLC and BRCA1, XOR.1-3 
Many studies on the prognostic and predictive 
values of BRCA1 and XOR in patients with NSCLC 
have been carried out previously. However, very few 
of them have addressed  the effect of neoadjuvant 
chemotherapy on pathological tissue markers.4-8 
This study aimed to determine the role of XOR 
activity in NSCLC and show the association of 
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BRCA1 and its prognosis. We also monitored the 
changes at the tissue level in the presence of these 
markers during neoadjuvant chemotherapy. 
 MATERIAL AND METHODS 
The present study was carried out on thirty-five cases 
of NSCLC, stage-III. The subjects had a history of 
neoadjuvant chemotherapy at Başkent University De-
partment of Oncology, between the years of 2006-
2012. The patients’ files were reviewed for the 
demographic factors of age, gender, stages of the dis-
ease at the time of diagnosis, administration of neoad-
juvant chemotherapies, disease-free survival rate, and 
overall survival outcomes. 
The mouse monoclonal antibody (MS110) and 
XOR ((DAKO Carpentaria California USA) were 
tested on patients during diagnosis and after the sur-
gery.  
Both antigens were stained with the antibodies 
and scored. The relations between the prognosis and 
characteristics of the disease, and treatment response 
were examined.  
All the sections stained with HE and IHC were 
examined blindly in terms of histological grade, 
without knowing the previous results of IHC. In all 
the cases, surrounding lung tissue in the tumor and 
existing sections were evaluated separately for both 
of the primer antibodies. Nuclear staining was done 
for BRCA1 and cytoplasmic staining done for 
XOR. 
Scoring for XOR: Staining density was graded 
as 0 (negative), 1 (weak), 2 (moderate), and 3 
(strongly positive), while the percentage of positive 
staining was scored as 0 (negative), 1 (1-9%), 2 (10-
49%), and 3 (50%), where 0-1 was graded as de-
creased and 2-3 was graded as increased.  
Scoring for BRCA: Staining density was graded 
as 0 (negative), 1 (weak), 2 (moderate), and 3 
(strongly positive). These patients were considered 
as BRCA1 (+) since their BRCA1 score was 3, and 
the patients were considered as BRCA1 (-) when 
their scores were lower than 3 (0, 1, and 2 graded as 
negative). The chemotherapy responses were ana-
lyzed by RECIST 1.0. 
STATISTICAL ANALYSIS 
Descriptive statistics were performed for the demo-
graphic and clinical features of the patients. Student’s 
t-test or Mann-Whitney U test was performed to com-
pare the numerical variables of the two independent 
groups while Chi-square test was performed to com-
pare the groups. Kaplan-Meier analysis was per-
formed to analyze the effect of the pre-determined 
factors on survival. The survival of different groups 
was compared using a log-rank test. Cox-regression 
test was used for the multivariate analysis of the fac-
tors associated with relapse-free survival and overall 
survival. The variables that had the value of p<0.2 in 
univariate analysis were included in the multivariable 
analysis. Statistical analyses were performed by 
SPSS, ver. 17.0 (SPSS Inc, Chicago, IL). The p>0.05 
was considered statistically significant. 
 RESULTS 
Thirty-five patients were included in the study. The 
median age was 60 among the range of 45-79. 
Twenty-nine (82.9%) patients were male, while 6 
(17.1%) were female. ECOG PS status of the pa-
tients: Seven of them were noted as 0 (20%), twenty-
four were noted as 1 (68.8%), while four were 
reported as 2 (11.4%). According to the histopatho-
logical examination of the patients, 16 patients 
(45.7%) were recorded as an adenocarcinoma, 15 
(37.1%) were having squamous cell carcinoma, 2 
(5.7%) were suffering from large cell carcinoma, and 
2 (5.7%) of the patients were in the group that was 
not subclassified. Among them, 19 patients (54.3%) 
were at stage IIIA, and 16 (45.7%) were at stage IIIB. 
After neoadjuvant chemotherapy, 29 patients were in 
partial remission, 3 patients had stable disease, 2 pa-
tients had progressive disease, and 1 patient showed 
complete response. Afterward, relapse was observed 
in 27 patients. The median progression was calcu-
lated until the assessment at 24 months. Twenty-two 
patients were lost during follow-ups. The demo-
graphic data of the patients are summarized in Table 
1. 
The median follow-up time of the patient was 
37.4 months, median survival was 38.5, and survival 
for 60 months was calculated as 33% (Figure 1). 
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Overall survival analysis indicated that those 
with the value of ECOG PS as 0 were more advanta-
geous than those with ECOG value of 2 (p=0.0039) 
(Figure 2).  
BRCA1 IHC interpretation of biopsy samples 
taken before chemotherapy of nine patients was pos-
itive and 26 patients showed a negative report. 
BRCA1 survival analysis indicates that there is a sta-
tistically significant difference between the two 
groups (p=0.047) (Figure 3). BRCA1 expression in 
operation blocks, obtained after neoadjuvant 
chemotherapy or radiotherapy did not change in any 
of the patients (Figure 4). After the operation, the re-
lation between positivity in BRCA1 and survival was 
found to be statistically significant in the negative di-
rection (p=0.047) (Figure 4). There was no statistical 
difference between histopathological investigation of 
the patients and their BRCA1 expression (Table 2).  
On the other hand, when we looked at XOR ac-
tivity, we found that XOR activity increased in the 
biopsy samples of 11 patients (31.4%) out of 35 while 
it decreased in the remaining 24 patients (66.6%).  
The relation between XOR activity and overall 
survival was found to be at the borderline level of sta-
tistical significance (p=0.05) (Figure 5). After the 
neoadjuvant treatment, the IHC and XOR findings of 
two patients, which was positive earlier, changed to 
negative (Table 3). There was no change in negative 
patients. In the operated patient samples, 9 (25.7%) 
showed positive, and 26 (74.3%) showed negative 
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Number of the patients 35 
Age, Median 61 (38–71) 
Gender 
Male 29 (82.9%) 
Female 6 (17.1%) 
Clinical stage 
IIIA 19 (54.3%) 
IIIB 16 (45.7%) 
Histology 
Adenocarcinoma 16 (45.7%) 
Squamous cell carcinoma 15 (42.9%) 
Large cell and others 4 (11.4%) 
ECOG Performance 
0 7 (20%) 
1 24 (68.6%) 
2 4 (11.4%)
TABLE 1:  Patient characteristics. 
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expression. Henceforth, there was no relation be-
tween post-operative tissue samples, XOR expres-
sion, and overall survival (Figure 6).  
According to the Kaplan Meier analysis performed 
for overall survival, ECOG PS (p=0.004%) 95% CI: 1.1-
4, BRCA1 positivity (p=0.047), and XOR positivity (in-
creased activity) (p=0.05) were included in the 
multivariable analysis since their p values were smaller 
than 0.2. In multivariable Cox regression, a significant 
relation was found only between ECOG performance 
score and overall survival (For ECOG, 2 vs. 0, H=10.7, 
95% CI: 1.7-65.2, p=0.01). Though the relation between 
BRCA1 positivity and overall survival rate was not 
found to be statistically significant, it was close to statis-
tical significance (H=2.6 95% CI: 0.95-7.05, p=0.062). 
For XOR, according to the results of Kaplan 
Meier analysis performed for relapse-free survival 
ECOG PS (p=0.03) and XOR positivity (p=0.12) 
were included in the multivariable analysis since their 
p values were smaller than 0.2. In the multivariable 
Cox regression analysis, no significant relation was 
found between the two parameters and relapse-free 
survival. The relation between ECOG performance 
score and relapse-free survival was only close to sta-
tistical significance though it was not significant. 
(H=4.2, 95% CI: 0.85-20.9, p=0.079) (Table 4). 
 DISCUSSION  
A better understanding of the biology of NSCLC 
might predict recurrences, further allowing us to in-
crease the quality of life, and to choose the most suit-
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BRCA1 Biopsy 
Negative Positive Total 
Adenocarcinoma 12 (75%) 4 (25%) P=0.941 
Squamous cell carcinoma 11 (75%) 4 (25%)  
Large cell and others 3 (75%) 1 (25%)  
Total 26 (74,2%) 9 (25,19%)  
TABLE 2:  Histopathology and BRCA1 relation.
XOR Biopsy 
Negative Positive Total 
Adenocarcinoma 11 (68.8%) 5 (31.3%) P=0.671 
Squamous cell carcinoma 11 (73.3%) 4 (26.7%)  
Large cell and others 2 (50%) 2 (50%)  
Total 24 (68.6%) 11 (31.4%)  
TABLE 3:  Histopathology and XOR relation.
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Total 
BRCA1 Biopsy Material (IHC) 
Positive 9 (25.7%) 
Negative 26 (74.3%) 
BRCA1 Operation Material (IHC) 
Positive 9 (25,7%) 
Negative 26 (74,31%) 
XOR Biopsy Material (IHC) 
Increased 11 (31.4%) 
Decreased 24 (68.6%) 
XOR postoperation Material (IHC) 
Increased 9 (25.7%) 
Decreased 26 (74.3%)
TABLE 4:  Results.
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able treatment for survival and recurrences. Previous 
evidence suggested that the measurement of BRCA1 
activity might be beneficial for the treatment strate-
gies of NSCLC.1-5 The mechanism for the develop-
ment of platinum resistance and its derivatives is 
closely associated with BRCA1 activity.6 Earlier, it 
was reported that the increase in BRCA expression 
is an unsatisfactory prognostic factor for lung cancer 
except for ovarian cancer, as well as, it is a bad pre-
dictive factor for cisplatin treatment.7-9 
The aim of this study was to investigate the 
prognostic role of BRCA1 and XOR activities espe-
cially in patients with locally advanced stage III of 
NSCLC. We found an increased BRCA1 level in 9 
out of 35 patients, with locally advanced NSCLC, 
during biopsy, and after the operation. The statistical 
significance between BRCA1 (+) and overall survival 
was observed as p=0.047. The patients with BRCA1 
positive were those who died earlier.  
On this basis, we could say that the level of 
BRCA1 increases, and could be a bad prognostic 
marker for survival if noted as negative. There was 
no significance found between BRCA1 expression 
and the stages. However, BRCA positivity was pres-
ent in 3 of 8 patients at stage III, and 3 of 10 patients 
at stage I. Therefore, this study predicted that the 
higher the stage, the more frequent it is numerically 
(Table 4). 
Previously, it was suggested that chemothera-
peutic drugs damage DNA in different ways and lack 
of BRCA1 function causes increased molecular sen-
sitivity in tumor cells and thus it is a predictive 
marker for the chemotherapy response in NSCLC.8 
BRCA1 is also involved in nucleotide excision repair 
like ERCC1. The negative expression of BRCA1 in-
creases cisplatin sensitivity, while its positive ex-
pression increases microtubule sensitivity.5  
However, it is difficult to clearly say that it is a 
predictive marker, as there were not enough patients 
in this study. The clinical data suggested that the tu-
mors with BRCA1 value show a low survival rate, 
and they should be given adjuvant chemotherapy. 
The prognosis of the patients with BRCA1 was not 
noted as unsatisfactory as compared to those without 
BRCA1, and we can infer that, if the number of the 
patients go up, it might be prognostic for overall sur-
vival.  
While it was reported in previous studies that 
chemotherapy causes the tumor tissues of markers, 
such as ERCC1, to shrink in various degrees.10 In this 
study, the subjects were noted as positive for BRCA1 
instead of negative. It is difficult to say that 
chemotherapy or radiotherapy does not have any ef-
fect on the IHC expression of this marker since there 
was a small number of positive BRCA1, just opposite 
to the data in previous literature.11 
Xanthine oxidase act as a rate-limiting enzyme 
in purine metabolism. It has been reported that lack of 
xanthine oxidoreductase activity is associated with 
the deterioration of various tumors, and has a bad 
prognostic factor.3,9,12-16 The decrease in XOR activ-
ity has been observed in a high histologic grade of 
large tumors and in many breast cancer cases that ex-
hibit high COX–2 expression with bad prognostic 
features, such as axillary lymph node retention. Also, 
a decrease in XOR activity was more apparent in the 
prognosis of the patients with gastric carcinoma.17-20 
Despite the low survival and deterioration asso-
ciated with decreased XOR activity, the appropriate 
cause is not fully understood. Out of 35 biopsy sam-
ples, which were negative, 24 belonged to 16 patients 
(66.6%) who died, and 8 (33.3%) to those who sur-
vived. The number of patients with a negative XOR 
value who died was twice as high as those with a pos-
itive value. However, there was no statistical signif-
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